PROK
ProKidney Corp.
NASDAQ: PROK · HEALTHCARE · BIOTECHNOLOGY
$1.82
-0.55% today
Updated 2026-04-29
Market cap
$552.59M
P/E ratio
—
P/S ratio
618.80x
EPS (TTM)
$-0.52
Dividend yield
—
52W range
$1 – $6
Volume
0.8M
ProKidney Corp. (PROK) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $76000.00 | $893000.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | +1075.0% |
| Cost of revenue | — | — | $1.98M | $3.04M | $3.17M | — | $5.72M |
| Gross profit | — | — | $-1.98M | $-3.04M | $-3.17M | $76000.00 | $-4.83M |
| Gross margin | — | — | — | — | — | 100.0% | -540.8% |
| R&D | $75.22M | $21.04M | $46.26M | $82.07M | $106.71M | $127.67M | $114.12M |
| SG&A | $4.16M | $5.67M | $8.86M | $70.94M | $44.81M | $56.08M | $51.78M |
| Operating income | $-79.38M | $-27.02M | $-55.11M | $-153.01M | $-151.52M | $-183.68M | $-165.01M |
| Operating margin | — | — | — | — | — | -241678.9% | -18477.8% |
| EBITDA | $-18.29M | $-26.06M | $-53.12M | $-143.99M | $-125.59M | $-158.49M | $-158.97M |
| EBITDA margin | — | — | — | — | — | -208542.1% | -17801.5% |
| EBIT | $-19.16M | $-27.02M | $-55.11M | $-147.02M | $-129.44M | $-163.92M | $-164.69M |
| Interest expense | $0.00 | $43000.00 | $2000.00 | $215000.00 | $12000.00 | $9000.00 | $4000.00 |
| Income tax | $361000.00 | $-232000.00 | $38000.00 | $896000.00 | $6.00M | $-598000.00 | — |
| Effective tax rate | -0.5% | 0.9% | -0.1% | -0.8% | -20.3% | 1.0% | 0.0% |
| Net income | $-79.61M | $-26.75M | $-55.15M | $-108.03M | $-35.47M | $-61.19M | $-68.99M |
| Net income growth (YoY) | — | +66.4% | -106.2% | -95.9% | +67.2% | -72.5% | -12.7% |
| Profit margin | — | — | — | — | — | -80507.9% | -7725.2% |